Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 212

1.

Ten recommendations for closing the credibility gap in reporting industry-sponsored clinical research: a joint journal and pharmaceutical industry perspective.

Mansi BA, Clark J, David FS, Gesell TM, Glasser S, Gonzalez J, Haller DG, Laine C, Miller CL, Mooney LA, Zecevic M.

Mayo Clin Proc. 2012 May;87(5):424-9. doi: 10.1016/j.mayocp.2012.02.009. No abstract available.

2.

Commenting on ten recommendations for closing the credibility gap in reporting industry-sponsored clinical research.

Stossel TP, Stell LK.

Mayo Clin Proc. 2012 Sep;87(9):925-6; author reply 926. doi: 10.1016/j.mayocp.2012.06.020. No abstract available.

3.

Proposed best practice for statisticians in the reporting and publication of pharmaceutical industry-sponsored clinical trials.

Matcham J, Julious S, Pyke S, O'Kelly M, Todd S, Seldrup J, Day S.

Pharm Stat. 2011 Jan-Feb;10(1):70-3. doi: 10.1002/pst.417.

PMID:
20187020
4.

Credibility of industry-sponsored clinical research: hype or hope?

Braillon A.

Mayo Clin Proc. 2012 Sep;87(9):925. doi: 10.1016/j.mayocp.2012.06.018. No abstract available.

6.

[Publication ethics: regulation of financial conflicts of interests in medical journals].

Kakuk P.

Lege Artis Med. 2011 Jan;21(1):65-71. Hungarian. No abstract available.

PMID:
21469379
7.

[Knowledge on feet of clay].

Dahlqvist R.

Lakartidningen. 2008 May 7-13;105(19):1405-6. Swedish. No abstract available.

PMID:
18574980
8.

Promoting transparency in pharmaceutical industry-sponsored research.

Ross JS, Gross CP, Krumholz HM.

Am J Public Health. 2012 Jan;102(1):72-80. doi: 10.2105/AJPH.2011.300187. Epub 2011 Nov 28.

9.

Trust in the medical literature--and Viewpoints in JAMA Internal Medicine.

Steinbrook R, Redberg RF.

JAMA Intern Med. 2013 Jun 24;173(12):1047-8. doi: 10.1001/jamainternmed.2013.6281. No abstract available.

PMID:
23609117
10.

Between the lines: navigating the uncharted territory of industry-sponsored research.

Davidoff F.

Health Aff (Millwood). 2002 Mar-Apr;21(2):235-42. No abstract available.

11.

Access to data from clinical trials sponsored by pharmaceutical companies.

West R.

Addiction. 2007 May;102(5):682-3. No abstract available.

PMID:
17493100
12.

Industry-funded breast cancer trials show more positive results.

Gardner A.

Int J Health Serv. 2007;37(3):591-3.

PMID:
17844937
13.

Pharmaceutical research: paradox, challenge or dilemma?

Sheikh AL.

East Mediterr Health J. 2006;12 Suppl 1:S42-9. Review.

PMID:
17037688
14.

The sins of ghostwriting.

Somberg JC.

Am J Ther. 2008 Jul-Aug;15(4):297-8. doi: 10.1097/MJT.0b013e318180f387. No abstract available.

PMID:
18645328
15.

The potential for bias in reporting of industry-sponsored clinical trials.

Pyke S, Julious SA, Day S, O'Kelly M, Todd S, Matcham J, Seldrup J.

Pharm Stat. 2011 Jan-Feb;10(1):74-9. doi: 10.1002/pst.429.

PMID:
21275037
16.
17.

Full-disclosure in industry-sponsored laboratory medicine research studies: statement by the Consortium of Laboratory Medicine Journal Editors.

Rifai N, Plebani M, Wu AH, Delanghe J, Brugnara C, Delvin E, Lamb EJ, Ness PM, Wick MR, Berg JP.

Clin Chim Acta. 2011 Mar 18;412(7-8):491-2. doi: 10.1016/j.cca.2010.12.015. Epub 2010 Dec 14. No abstract available.

PMID:
21159312
18.
19.

Bias in the design, interpretation, and publication of industry-sponsored clinical research.

Hammerschmidt D.

Minn Med. 2008 Jun;91(6):46-7. No abstract available.

PMID:
18616022
20.

[Ghostwriting].

Haug C.

Tidsskr Nor Laegeforen. 2008 May 1;128(9):1039. Norwegian. No abstract available.

Items per page

Supplemental Content

Write to the Help Desk